AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24410736 — intervention group
Group type: COMPARATOR
Intervention: Standard PD solutions
Number of subjects: 88
Study 24410736 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer PD duration
Number of subjects: 88
Study 24410736 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-6 level
Number of subjects: 88
Study 24410736 — intervention group
Group type: COMPARATOR
Intervention: Biocompatible PD solutions
Number of subjects: 88
Study 22696191 — intervention group
Group type: EXPERIMENTAL
Intervention: Local TCA injections
Number of subjects: 45
Study 22696191 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 45
Study 19450157 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (60-70% of maximal heart rate; 60 minutes per day; 3 days per week for 12 weeks)
Number of subjects: 20
Study 19450157 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-metabolic syndrome, n = 22)
Number of subjects: 20
Study 17585669 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianying point-injection combined with massage
Number of subjects: 140
Study 17585669 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture therapy
Number of subjects: 140
Study 15366591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianhuang Huoxue Tongluo Decoction (THTD) given additionally starting from the 6th day of disease for 30 days
Number of subjects: 72
Study 15366591 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine treatment
Number of subjects: 72
Study 15366591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianhuang Huoxue Tongluo Decoction (THTD)
Number of subjects: 72
Study 11264684 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 206
Study 11264684 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 206
Study 11264684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 9735727 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge planning protocol coordinated by nurse/social worker teams using the Discharge Planning Questionnaire (DPQ)
Number of subjects: 507
Study 9735727 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital discharge planning protocol
Number of subjects: 507
Study 7987190 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines
Number of subjects: 140
Study 7987190 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual
Number of subjects: 140
Study 7987190 — intervention group
Group type: COMPARATOR
Intervention: General Information
Number of subjects: 140
Study 3055454 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg over 3 d)
Number of subjects: 20
Study 3055454 — intervention group
Group type: COMPARATOR
Intervention: Quinine (10 mg/kg 3 times daily for 5 d)
Number of subjects: 20
Study 3055454 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 20
Study 3055454 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 20
Study 3055454 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro results for chloroquine
Number of subjects: 20
Study 3055454 — intervention group
Group type: COMPARATOR
Intervention: In vitro results for quinine
Number of subjects: 20
Study 31169795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB)
Number of subjects: 670
Study 31169795 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise
Number of subjects: 670
Study 31169795 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise
Number of subjects: 670
Study 27642035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful chocolate consumption
Number of subjects: 258
Study 27642035 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mindful chocolate consumption
Number of subjects: 258
Study 27642035 — intervention group
Group type: COMPARATOR
Intervention: Mindful cracker consumption
Number of subjects: 258
Study 27642035 — intervention group
Group type: COMPARATOR
Intervention: Non-mindful cracker consumption
Number of subjects: 258
Study 26301706 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game exercise training (VGG)
Number of subjects: 36
Study 26301706 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise training (TG)
Number of subjects: 36
Study 24041408 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 165
Study 24041408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone, Olanzapine, Quetiapine
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 16073
Study 21851976 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 16073
Study 19816208 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of PRBC at a rate of 1 mL/kg/h (Group A)
Number of subjects: 43
Study 19816208 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of PRBC at a rate of 3 mL/kg/h (Group B)
Number of subjects: 43
Study 19816208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 43
Study 16970804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 32
Study 16970804 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 32
Study 15480842 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa treatment
Number of subjects: 16
Study 15480842 — intervention group
Group type: COMPARATOR
Intervention: untreated condition
Number of subjects: 16
Study 11835115 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression class I stockings (18‐21 mm Hg) on the left leg and class II stockings (25‐32 mm Hg) on the right (group 1)
Number of subjects: 42
Study 11835115 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression class II stockings (25‐32 mm Hg) on the left leg and class I stockings (18‐21 mm Hg) on the right (group 2)
Number of subjects: 42
Study 11835115 — intervention group
Group type: COMPARATOR
Intervention: No stockings (control group)
Number of subjects: 42
Study 9462678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy plus tamoxifen
Number of subjects: 104
Study 9462678 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose chemotherapy plus tamoxifen
Number of subjects: 104
Study 9462678 — intervention group
Group type: COMPARATOR
Intervention: Control (early stage breast cancer not treated with systemic therapy)
Number of subjects: 104
Study 9462678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 104
Study 9462678 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose chemotherapy
Number of subjects: 104
Study 7993989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (600 mg) after overnight fasting
Number of subjects: 6
Study 7993989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (600 mg) after a fat‐ and protein‐rich breakfast
Number of subjects: 6
Study 7993989 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine with food
Number of subjects: 6
Study 7993989 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine with or without food
Number of subjects: 6
Study 2597067 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium-YAG laser goniotomy
Number of subjects: 10
Study 2597067 — intervention group
Group type: COMPARATOR
Intervention: Surgical goniotomy
Number of subjects: 10
Study 1097470 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg twice daily
Number of subjects: 0
Study 1097470 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 250 mg six-hourly
Number of subjects: 0
Study 31517876 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of standardized ashwagandha extract (Shoden) once daily
Number of subjects: 60
Study 28083972 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 5598
Study 28083972 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 5598
Study 28083972 — intervention group
Group type: COMPARATOR
Intervention: SGLT2 inhibitors (including canagliflozin, dapagliflozin, empagliflozin)
Number of subjects: 5598
Study 24969352 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations (FF) intervention
Number of subjects: 148
Study 23602514 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal‐iBA
Number of subjects: 910
Study 23602514 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 910
Study 21153029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg
Number of subjects: 130
Study 21153029 — intervention group
Group type: COMPARATOR
Intervention: Control (Aspirin 100 mg and Clopidogrel 75 mg)
Number of subjects: 130
Study 19644260 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual surgery
Number of subjects: 75
Study 19644260 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 75
Study 17851280 — intervention group
Group type: EXPERIMENTAL
Intervention: SWL at 90 shocks/min
Number of subjects: 116
Study 17851280 — intervention group
Group type: COMPARATOR
Intervention: SWL at 120 shocks/min
Number of subjects: 116
Study 15172408 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (10 to 20 mg/day)
Number of subjects: 36
Study 15172408 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (20 to 40 mg/day)
Number of subjects: 36
Study 15172408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 11281231 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma renin activity in white children (7.1 +/- 3.6 ng/mL/h)
Number of subjects: 264
Study 11281231 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of renin activity with blood pressure (BP)
Number of subjects: 264
Study 11281231 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of renin activity with insulin resistance index
Number of subjects: 264
Study 11281231 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of children with high insulin resistance index and renin values
Number of subjects: 264
Study 11281231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate factor analysis of risk variables of insulin resistance syndrome
Number of subjects: 264
Study 9314399 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 580
Study 9314399 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 580
Study 8420268 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (told that intravenous medication was given)
Number of subjects: 62
Study 8420268 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (told that the injection was to elicit their usual pain)
Number of subjects: 62
Study 8420268 — intervention group
Group type: COMPARATOR
Intervention: Physician A
Number of subjects: 62
Study 8420268 — intervention group
Group type: COMPARATOR
Intervention: Physician B
Number of subjects: 62
Study 8420268 — intervention group
Group type: COMPARATOR
Intervention: Physician C
Number of subjects: 62
Study 3737031 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole (990 mg/225 mg/day)
Number of subjects: 9
Study 3737031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29682590 — intervention group
Group type: COMPARATOR
Intervention: Standard dose HBV vaccination (3 doses of 20μg) in healthy controls
Number of subjects: 0
Study 29682590 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses of 20μg HBV vaccination
Number of subjects: 0
Study 29682590 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses of 40μg HBV vaccination
Number of subjects: 0
Study 27325864 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred.
Number of subjects: 152
Study 27325864 — intervention group
Group type: COMPARATOR
Intervention: Placebo, matching regorafenib, orally on days 1 to 21 of each 28-day cycle until disease progression or prohibitive adverse events occurred.
Number of subjects: 152
Study 27325864 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 152
Study 27325864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 24695091 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg/day for 14 days
Number of subjects: 324
Study 24695091 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) 4000 AxaIU (0.4 ml)/day for 14 days
Number of subjects: 324
Study 24695091 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/day for 14 days
Number of subjects: 324
Study 22480715 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Symptom Scale‐Interview (PSS‐I)
Number of subjects: 167
Study 22480715 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐report PTSD Diagnostic Scale (PDS)
Number of subjects: 167
Study 20053673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - recommendations about healthy habits and adherence to treatment in group sessions for non-risk patients; individual visits by a geriatrician for at-risk patients.
Number of subjects: 620
Study 20053673 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - usual care.
Number of subjects: 620
Study 20053673 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison between IG and CG.
Number of subjects: 620
Study 18397549 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (mean modal dose 12.0 mg/day, average duration 241 days)
Number of subjects: 60
Study 18397549 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (mean modal dose 4.0 mg/day, average duration 86 days)
Number of subjects: 60
Study 18397549 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (after switch)
Number of subjects: 60
Study 16084852 — intervention group
Group type: EXPERIMENTAL
Intervention: TTT haplotype (3435T, 1236T, and 2677T)
Number of subjects: 20
Study 16084852 — intervention group
Group type: COMPARATOR
Intervention: CGC haplotype (3435C, 2677G, and 1236C)
Number of subjects: 20
Study 12437647 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori infection
Number of subjects: 93
Study 12437647 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (without MGUS)
Number of subjects: 93
Study 12437647 — intervention group
Group type: COMPARATOR
Intervention: H. pylori infection diagnosis rates
Number of subjects: 93
Study 12437647 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori therapy
Number of subjects: 93
Study 10692734 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-based triple eradication regimen (Group A, n = 39)
Number of subjects: 73
Study 10692734 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone followed by long-term famotidine 20 mg daily (Group B, n = 34)
Number of subjects: 73
Study 7581968 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) replacement therapy for 6 months
Number of subjects: 30
Study 1617528 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive approach
Number of subjects: 57
Study 1617528 — intervention group
Group type: COMPARATOR
Intervention: Invasive approach
Number of subjects: 57
Study 6712754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pulse methotrexate therapy (2.5-5.0 mg every 12 hours in 3 consecutive doses per week)
Number of subjects: 37
Study 6712754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pulse methotrexate therapy
Number of subjects: 37
Study 6712754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31037566 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 56
Study 31037566 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 56
Study 29864374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical impact simulator
Number of subjects: 45
Study 26421810 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg orally 2 hours before surgery and 24 hours after surgery)
Number of subjects: 70
Study 26421810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 26421810 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg)
Number of subjects: 70
Study 26421810 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 70
Study 24333007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid/Laropiprant 1g/20mg for 4 weeks followed by 2g/40mg for 6 weeks
Number of subjects: 82
Study 24333007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid/Laropiprant
Number of subjects: 82
Study 22322110 — intervention group
Group type: EXPERIMENTAL
Intervention: +6D high water content daily disposable lens
Number of subjects: 39
Study 22322110 — intervention group
Group type: EXPERIMENTAL
Intervention: -6D high water content daily disposable lens
Number of subjects: 39
Study 19948382 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone dosing condition (19.7 mg for extreme pain, 15.0 mg for some pain, 12.8 mg for no pain)
Number of subjects: 69
Study 19948382 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone dosing condition
Number of subjects: 69
Study 18426421 — intervention group
Group type: EXPERIMENTAL
Intervention: +0.75 D lens addition
Number of subjects: 29
Study 18426421 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.50 D lens addition
Number of subjects: 29
Study 18426421 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.25 D lens addition
Number of subjects: 29
Study 18426421 — intervention group
Group type: EXPERIMENTAL
Intervention: +3.00 D lens addition
Number of subjects: 29
Study 18426421 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Delta base-in prism with +1.50 D lens addition
Number of subjects: 29
Study 18426421 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.25 D lens addition with 6-Delta base-in prism
Number of subjects: 29
Study 15951075 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand Elevation test
Number of subjects: 48
Study 15951075 — intervention group
Group type: COMPARATOR
Intervention: Tinel's test
Number of subjects: 48
Study 15951075 — intervention group
Group type: COMPARATOR
Intervention: Phalen's test
Number of subjects: 48
Study 14703266 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-in center program that eliminated barriers to access to services
Number of subjects: 393
Study 14703266 — intervention group
Group type: EXPERIMENTAL
Intervention: Apartment program with subsidized apartments and services under participants' control
Number of subjects: 393
Study 14703266 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual continuum of care)
Number of subjects: 393
Study 10388426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron 0.15 mg/kg with induction of anesthesia
Number of subjects: 0
Study 10388426 — intervention group
Group type: COMPARATOR
Intervention: Placebo of normal saline 0.3 ml/kg with induction of anesthesia
Number of subjects: 0
Study 8710717 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-containing mouthrinse (0.02 M alum), rinsed once daily for 30 seconds
Number of subjects: 48
Study 8710717 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 48
Study 1948121 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide plus flutamide
Number of subjects: 603
Study 1948121 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide plus placebo
Number of subjects: 603
Study 6841506 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (mean daily dose 44.2 mg/day)
Number of subjects: 66
Study 6841506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 6841506 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 66
Study 6841506 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate and reading instruction
Number of subjects: 66
Study 6841506 — intervention group
Group type: COMPARATOR
Intervention: Placebo and reading instruction
Number of subjects: 66
Study 31940698 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (1000 U/kg every 48 hours for six doses, then 400 U/kg three times per week until 32 weeks postmenstrual age)
Number of subjects: 941
Study 31940698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous saline and sham injections)
Number of subjects: 941
Study 31940698 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 941
Study 31940698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 941
Study 31607143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (24-hour mean systolic BP ≤130 mm Hg)
Number of subjects: 199
Study 31607143 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (24-hour mean systolic BP ≤145 mm Hg)
Number of subjects: 199
Study 31607143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 199
Study 31607143 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 199